On February 22, 2025, the "China Intracranial Metastases Consortium" (CLAIM) held its founding meeting and the first Xuanwu Intracranial Metastases Forum in Beijing. The event brought together nearly 170 experts and scholars from 108 hospitals, spanning oncology, radiotherapy, neurosurgery, pathology, and imaging departments, to discuss multidisciplinary approaches to treating intracranial metastases, intending to enhance patient survival.

On November 25, 2024, Qingdao Baheal Medical Co., Ltd. (301015.SZ, hereinafter referred to as "Baheal Medical") announced that it has entered an exclusive commercialization partnership with ZAP Surgical Systems, Inc. (hereinafter referred to as "ZAP"), a global leader in radiosurgical robots.

November 14, 2024 — Qingdao Baheal Medical INC. (“Baheal Medical”, stock code: 301015.SZ) announced that its wholly-owned subsidiary, Beijing Baheal ZHIHE Medical Achievement Transformation Service Co., Ltd., has signed a marketing cooperation agreement with Beijing Biostar Biopharmaceutical Co., Ltd. (“Biostar”, stock code: 2563.HK). Under the agreement, Baheal Medical will obtain exclusive marketing rights in mainland China for Biostar’s independently developed Class 1 innovative drug, Utidelone Injection (brand name: UTIDE®). Baheal Medical will make a non-refundable upfront payment of RMB 50 million to Biostar, and additional milestone payments based on development and sales progress. In return, Biostar will pay Baheal Pharma a tiered promotion service fee based on annual terminal sales.

Tarcine BioMed, a subsidiary of Baheal Pharma Group, has announced that its independently developed EB Virus Rta Protein IgG Antibody Detection Kit (Chemiluminescent Immunoassay) has been approved by the National Medical Products Administration. This third-generation diagnostic kit for nasopharyngeal cancer, based on a fully automated magnetic particle chemiluminescence platform, offers more stable results and meets diverse clinical diagnostic needs.

On October 26, 2024, the Second Annual Conference of the National Infectious Disease Medical Center's Infectious Disease Specialty Alliance was held in Kunming, Yunnan. During the event, a strategic cooperation agreement was signed between Baheal Pharma and the National Infectious Disease Medical Center (Beijing) and Beijing Ditan Hospital. This partnership aims to address major national needs in infectious disease prevention and treatment, focusing on technology innovation, result transformation, and talent cultivation. Attending the signing ceremony were Jin Ronghua, Director of the National Center for Infectious Diseases (Beijing) and President of Beijing Ditan Hospital; Chen Xiaoyou, Executive Vice President of Beijing Ditan Hospital; Yang Zhiyun, Vice President; Tian Xin, Deputy Secretary; Li Xin, Director of the Science and Technology Department; Song Qing, Director and President of Baiyang Pharmaceutical Group; Wang Biquan, Vice President of Innovative Drugs and Devices; and Zhang Shuying, Strategic Customer Director.